Base de dados : MEDLINE
Pesquisa : D02.241.223.100.300.595.100 [Categoria DeCS]
Referências encontradas : 3006 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 301 ir para página                         

  1 / 3006 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28771575
[Au] Autor:Tillmann S; Pereira VS; Liebenberg N; Christensen AK; Wegener G
[Ad] Endereço:Department of Clinical Medicine, Translational Neuropsychiatry Unit, Aarhus University, Aarhus, Denmark.
[Ti] Título:ZL006, a small molecule inhibitor of PSD-95/nNOS interaction, does not induce antidepressant-like effects in two genetically predisposed rat models of depression and control animals.
[So] Source:PLoS One;12(8):e0182698, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:N-methyl-D-aspartate receptor (NMDA-R) antagonists and nitric oxide inhibitors have shown promising efficacy in depression but commonly induce adverse events. To circumvent these, a more indirect disruption of the nitric oxide synthase/postsynaptic density protein 95 kDa complex at the NMDA-R has been proposed. This disruption can be achieved using small molecule inhibitors such as ZL006, which has attracted attention as ischemic stroke therapy in rodents and has been proposed as a potential novel treatment for depression. Based on this, our aim was to translate these findings to animal models of depression to elucidate antidepressant-like properties in more detail. In the present study, we administered ZL006 to two established animal models of depression and control rodents. Following treatment, we measured locomotion in the Open Field and depressive-like behavior in the Forced Swim Test and Tail Suspension Test. Our experimental designs included the use of different species (rats, mice), strains (Flinders Sensitive Line rats, Flinders Resistant Line rats, Wistar Kyoto rats, Wistar Hanover rats, Sprague Dawley rats, B6NTac mice), routes of administration (intraperitoneal, intracerebroventricular), times of administration (single injection, repeated injections), treatment regimens (acute, sustained), and doses (5, 10, 15, 50 mg/kg). ZL006 did not affect behavior in any of the described settings. On a molecular level, ZL006 significantly reduced total nitrate/nitrite concentrations in the cerebellum, supporting that it is capable of reducing nitric oxide metabolites in the brain. Future studies using different experimental parameters are needed to further investigate the behavioral profile of ZL006.
[Mh] Termos MeSH primário: Ácidos Aminossalicílicos/administração & dosagem
Comportamento Animal/efeitos dos fármacos
Benzilaminas/administração & dosagem
Depressão/genética
Depressão/psicologia
[Mh] Termos MeSH secundário: Ácidos Aminossalicílicos/farmacologia
Animais
Benzilaminas/farmacologia
Depressão/tratamento farmacológico
Modelos Animais de Doenças
Relação Dose-Resposta a Droga
Predisposição Genética para Doença
Infusões Intraventriculares
Injeções Intraperitoneais
Masculino
Camundongos
Ratos
Ratos Sprague-Dawley
Ratos Wistar
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Aminosalicylic Acids); 0 (Benzylamines); 0 (ZL006 compound)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170829
[Lr] Data última revisão:
170829
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170804
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0182698


  2 / 3006 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28608717
[Au] Autor:Troncone E; Monteleone G
[Ad] Endereço:a Department of Systems Medicine , University of Rome "Tor Vergata" , Rome , Italy.
[Ti] Título:The safety of non-biological treatments in Ulcerative Colitis.
[So] Source:Expert Opin Drug Saf;16(7):779-789, 2017 Jul.
[Is] ISSN:1744-764X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: Ulcerative colitis (UC) is a chronic inflammatory bowel disease with a relapsing-remitting course that determines significant morbidity and can associate with local complications and/or extra-intestinal manifestations. Pharmacological therapies are often required for a lifetime with possible risks of toxicity and side effects. Areas covered: Non-biological therapies (i.e. aminosalicylates, corticosteroids and immunosuppressive drugs) are widely used in UC patients for controlling the active phases of the disease and maintaining remission. Expert Opinion: Aminosalycilates have a good safety profile with a low risk of idiosyncrasic reactions. In contrast, the use of corticosteroids and immunosuppressive drugs can associate with unacceptable side effects, some of which are potentially life threatening. Mechanisms underlying the development of these side effects are not fully understood and strategies aimed to prevent them have not yet been standardized. However, clinicians should monitor the patients during therapy to recognize the adverse events at an early stage of the occurrence. New drugs that selectively target molecules involved in the amplification of the ongoing mucosal inflammation are currently under investigation. Preliminary data indicate that such compounds have better overall safety and tolerability than corticosteroids and immunosuppressive drugs.
[Mh] Termos MeSH primário: Colite Ulcerativa/tratamento farmacológico
Desenho de Drogas
Fármacos Gastrointestinais/uso terapêutico
[Mh] Termos MeSH secundário: Ácidos Aminossalicílicos/efeitos adversos
Ácidos Aminossalicílicos/uso terapêutico
Animais
Colite Ulcerativa/fisiopatologia
Fármacos Gastrointestinais/efeitos adversos
Fármacos Gastrointestinais/farmacologia
Glucocorticoides/efeitos adversos
Glucocorticoides/uso terapêutico
Seres Humanos
Imunossupressores/efeitos adversos
Imunossupressores/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Aminosalicylic Acids); 0 (Gastrointestinal Agents); 0 (Glucocorticoids); 0 (Immunosuppressive Agents)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170717
[Lr] Data última revisão:
170717
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170614
[St] Status:MEDLINE
[do] DOI:10.1080/14740338.2017.1340936


  3 / 3006 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27769809
[Au] Autor:Mahadevan U; McConnell RA; Chambers CD
[Ad] Endereço:Department of Medicine, Division of Gastroenterology, University of California, San Francisco, San Francisco, California. Electronic address: uma.mahadevan@ucsf.edu.
[Ti] Título:Drug Safety and Risk of Adverse Outcomes for Pregnant Patients With Inflammatory Bowel Disease.
[So] Source:Gastroenterology;152(2):451-462.e2, 2017 Feb.
[Is] ISSN:1528-0012
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The management of the pregnant patient with inflammatory bowel disease is complicated by multiple providers, misinformation, and a disease entity that, particularly when active, can adversely affect pregnancy outcomes. This article seeks to frame the debate on medication safety in pregnancy and lactation using the US Food and Drug Administration's new Pregnancy and Lactation Labeling Rule and the most up-to-date safety information to discuss the risks and benefits of using each class of inflammatory bowel disease medication.
[Mh] Termos MeSH primário: Ácidos Aminossalicílicos/uso terapêutico
Antibacterianos/uso terapêutico
Produtos Biológicos/uso terapêutico
Anormalidades Congênitas/epidemiologia
Glucocorticoides/uso terapêutico
Fatores Imunológicos/uso terapêutico
Doenças Inflamatórias Intestinais/tratamento farmacológico
Complicações na Gravidez/tratamento farmacológico
[Mh] Termos MeSH secundário: Aleitamento Materno
Rotulagem de Medicamentos
Feminino
Seres Humanos
Gravidez
Resultado da Gravidez/epidemiologia
Risco
Estados Unidos
United States Food and Drug Administration
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Aminosalicylic Acids); 0 (Anti-Bacterial Agents); 0 (Biological Products); 0 (Glucocorticoids); 0 (Immunologic Factors)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170605
[Lr] Data última revisão:
170605
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:161023
[St] Status:MEDLINE


  4 / 3006 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27760767
[Au] Autor:Matsui F; Babitz SA; Rhee A; Hile KL; Zhang H; Meldrum KK
[Ad] Endereço:Department of Urology, Indiana University School of Medicine, Indianapolis, Indiana; and.
[Ti] Título:Mesenchymal stem cells protect against obstruction-induced renal fibrosis by decreasing STAT3 activation and STAT3-dependent MMP-9 production.
[So] Source:Am J Physiol Renal Physiol;312(1):F25-F32, 2017 Jan 01.
[Is] ISSN:1522-1466
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:STAT3 is a transcription factor implicated in renal fibrotic injury, but the role of STAT3 in mesenchymal stem cell (MSC)-induced renoprotection during renal fibrosis remains unknown. We hypothesized that MSCs protect against obstruction-induced renal fibrosis by downregulating STAT3 activation and STAT3-induced matrix metalloproteinase-9 (MMP-9) expression. Male Sprague-Dawley rats underwent renal arterial injection of vehicle or MSCs (1 × 10 /rat) immediately before sham operation or induction of unilateral ureteral obstruction (UUO). The kidneys were harvested after 4 wk and analyzed for collagen I and III gene expression, collagen deposition (Masson's trichrome), fibronectin, α-smooth muscle actin, active STAT3 (p-STAT3), MMP-9, and tissue inhibitor of matrix metalloproteinases 1 (TIMP-1) expression. In a separate arm, the STAT3 inhibitor S3I-201 (10 mg/kg) vs. vehicle was administered to rats intraperitoneally just after induction of UUO and daily for 14 days thereafter. The kidneys were harvested after 2 wk and analyzed for p-STAT3 and MMP-9 expression, and collagen and fibronectin deposition. Renal obstruction induced a significant increase in collagen, fibronectin, α-SMA, p-STAT3, MMP-9, and TIMP-1 expression while exogenously administered MSCs significantly reduced these indicators of obstruction-induced renal fibrosis. STAT3 inhibition with S3I-201 significantly reduced obstruction-induced MMP-9 expression and tubulointerstitial fibrosis. These results demonstrate that MSCs protect against obstruction-induced renal fibrosis, in part, by decreasing STAT3 activation and STAT3-dependent MMP-9 production.
[Mh] Termos MeSH primário: Benzenossulfonatos/farmacologia
Metaloproteinase 9 da Matriz/metabolismo
Células Mesenquimais Estromais/metabolismo
Fator de Transcrição STAT3/metabolismo
Obstrução Ureteral/metabolismo
[Mh] Termos MeSH secundário: Ácidos Aminossalicílicos/farmacologia
Animais
Fibronectinas/metabolismo
Fibrose/metabolismo
Rim/efeitos dos fármacos
Rim/metabolismo
Nefropatias/tratamento farmacológico
Nefropatias/metabolismo
Masculino
Ratos Sprague-Dawley
Obstrução Ureteral/patologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Aminosalicylic Acids); 0 (Benzenesulfonates); 0 (Fibronectins); 0 (NSC 74859); 0 (STAT3 Transcription Factor); 0 (Stat3 protein, rat); EC 3.4.24.35 (Matrix Metalloproteinase 9); EC 3.4.24.35 (Mmp9 protein, rat)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170906
[Lr] Data última revisão:
170906
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161021
[St] Status:MEDLINE
[do] DOI:10.1152/ajprenal.00311.2016


  5 / 3006 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27716592
[Au] Autor:Kandula M; Sunil Kumar KB; Palanichamy S; Rampal A
[Ad] Endereço:Cellix Bio Pvt Ltd, Plot No 1177B, Road Number 56, Jubilee Hills, Hyderabad 500033, India. Electronic address: kmahesh@cellixbio.com.
[Ti] Título:Discovery and preclinical development of a novel prodrug conjugate of mesalamine with eicosapentaenoic acid and caprylic acid for the treatment of inflammatory bowel diseases.
[So] Source:Int Immunopharmacol;40:443-451, 2016 Nov.
[Is] ISSN:1878-1705
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Mesalamine (5-ASA) is one of the drugs indicated as first line therapy in ulcerative colitis for induction and maintenance of remission. Sulfasalazine and formulations of 5-ASA (pH-dependent and controlled release formulations) were developed to minimize the systemic absorption and maximize the delivery of the mesalamine to colon. Although, its efficacy and safety is well documented there are approximately 30% nonresponders to 5-ASA therapy. This necessitates the need for novel therapeutic options to improve the efficacy and safety of the currently available 5-ASA therapy. CLX-103 is a novel, patented prodrug molecular conjugate of mesalamine, eicosapentaenoic acid and caprylic acid designed to offer incremental benefits over the currently approved 5-ASA formulations. Results of in vitro and in vivo studies showed that CLX-103, was stable in simulated gastric fluid, but undergoes enzymatic hydrolysis in the small/large intestines to release the active moiety. Our data also showed that the active moiety is retained in the targeted intestinal tissues (ileum and colon) over a longer period of time in relation to sulfasalazine. The in vitro data supports the observed in vivo plasma kinetics of 5-ASA characterized by longer T , low C after the oral administration of CLX-103. Efficacy study of CLX-103 in acute dextran sodium sulfate (DSS) mouse colitis model showed improved potency measured as Disease Activity Index (DAI) and histological scores in the colon as compared to sulfasalazine. These findings indicate that CLX-103 could offer a differentiated drug product which is more efficacious and safer than the currently approved 5-ASA formulations in the treatment of inflammatory bowel diseases.
[Mh] Termos MeSH primário: Ácidos Aminossalicílicos/uso terapêutico
Caprilatos/uso terapêutico
Colite/tratamento farmacológico
Colo/efeitos dos fármacos
Ácido Eicosapentaenoico/análogos & derivados
Ácido Eicosapentaenoico/uso terapêutico
Doenças Inflamatórias Intestinais/tratamento farmacológico
Pró-Fármacos/uso terapêutico
[Mh] Termos MeSH secundário: Animais
Caprilatos/síntese química
Colite/induzido quimicamente
Colo/metabolismo
Colo/patologia
Sulfato de Dextrana
Descoberta de Drogas
Avaliação Pré-Clínica de Medicamentos
Ácido Eicosapentaenoico/síntese química
Seres Humanos
Masculino
Mesalamina/química
Mesalamina/uso terapêutico
Camundongos
Camundongos Endogâmicos C57BL
Ratos
Ratos Sprague-Dawley
Sulfassalazina/uso terapêutico
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Aminosalicylic Acids); 0 (CLX-103); 0 (Caprylates); 0 (Prodrugs); 3XC8GUZ6CB (Sulfasalazine); 4Q81I59GXC (Mesalamine); 9042-14-2 (Dextran Sulfate); AAN7QOV9EA (Eicosapentaenoic Acid); OBL58JN025 (octanoic acid)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170417
[Lr] Data última revisão:
170417
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161008
[St] Status:MEDLINE


  6 / 3006 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
[PMID]:27372735
[Au] Autor:Lim WC; Wang Y; MacDonald JK; Hanauer S
[Ad] Endereço:Department of Gastroenterology and Hepatology, Tan Tock Seng Hospital, 11 Jalan Tan Tock Seng, Singapore, Singapore, S 308433.
[Ti] Título:Aminosalicylates for induction of remission or response in Crohn's disease.
[So] Source:Cochrane Database Syst Rev;7:CD008870, 2016 Jul 03.
[Is] ISSN:1469-493X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Randomized trials investigating the efficacy of aminosalicylates for the treatment of mildly to moderately active Crohn's disease have yielded conflicting results. A systematic review was conducted to critically examine current available data on the efficacy of sulfasalazine and mesalamine for inducing remission or clinical response in these patients. OBJECTIVES: To evaluate the efficacy of aminosalicylates compared to placebo, corticosteroids, and other aminosalicylates (alone or in combination with corticosteroids) for the treatment of mildly to moderately active Crohn's disease. SEARCH METHODS: We searched PubMed, EMBASE, MEDLINE and the Cochrane Central Library from inception to June 2015 to identify relevant studies. There were no language restrictions. We also searched reference lists from potentially relevant papers and review articles, as well as proceedings from annual meetings (1991-2015) of the American Gastroenterological Association and American College of Gastroenterology. SELECTION CRITERIA: Randomized controlled trials that evaluated the efficacy of sulfasalazine or mesalamine in the treatment of mildly to moderately active Crohn's disease compared to placebo, corticosteroids, and other aminosalicylates (alone or in combination with corticosteroids) were included. DATA COLLECTION AND ANALYSIS: Data extraction and assessment of methodological quality was independently performed by the investigators and any disagreement was resolved by discussion and consensus. We assessed methodological quality using the Cochrane risk of bias tool. The overall quality of the evidence supporting the outcomes was evaluated using the GRADE criteria. The primary outcome measure was a well defined clinical endpoint of induction of remission or response to treatment. Secondary outcomes included mean Crohn's disease activity index (CDAI) scores, adverse events, serious adverse events and withdrawal due to adverse events. For dichotomous outcomes we calculated the pooled risk ratio (RR) and corresponding 95% confidence interval (CI) using a random-effects model. For continuous outcomes we calculated the mean difference (MD) and 95% CI using a random-effects model. Sensitivity analyses based on a fixed-effect model and duration of therapy were conducted where appropriate. MAIN RESULTS: Twenty studies (2367 patients) were included. Two studies were judged to be at high risk of bias due to lack of blinding. Eight studies were judged to be at high risk of bias due to incomplete outcomes data (high drop-out rates) and potential selective reporting. The other 10 studies were judged to be at low risk of bias. A non-significant trend in favour of sulfasalazine over placebo for inducing remission was observed, with benefit confined mainly to patients with Crohn's colitis. Forty-five per cent (63/141) of sulfasalazine patients entered remission at 17-18 weeks compared to 29% (43/148) of placebo patients (RR 1.38, 95% CI 1.00 to 1.89, 2 studies). A GRADE analysis rated the overall quality of the evidence supporting this outcome as moderate due to sparse data (106 events). There was no difference between sulfasalazine and placebo in adverse event outcomes. Sulfasalazine was significantly less effective than corticosteroids and inferior to combination therapy with corticosteroids (RR 0.64, 95% CI 0.47 to 0.86, 1 study, 110 patients). Forty-three per cent (55/128) of sulfasalazine patients entered remission at 17 to 18 weeks compared to 60% (79/132) of corticosteroid patients (RR 0.68, 95% CI 0.51 to 0.91; 2 studies, 260 patients). A GRADE analysis rated the overall quality of the evidence supporting this outcome as moderate due to sparse data (134 events). Sulfasalazine patients experienced significantly fewer adverse events than corticosteroid patients (RR 0.43, 95% CI 0.22 to 0.82; 1 study, 159 patients). There was no difference between sulfasalazine and corticosteroids in serious adverse events or withdrawal due to adverse events. Olsalazine was less effective than placebo in a single trial (RR 0.36, 95% CI 0.18 to 0.71; 91 patients). Low dose mesalamine (1 to 2 g/day) was not superior to placebo for induction of remission. Twenty-three per cent (43/185) of low dose mesalamine patients entered remission at week 6 compared to 15% (18/117) of placebo patients (RR = 1.46, 95% CI 0.89 to 2.40; n = 302). A GRADE analysis indicated that the overall quality of the evidence supporting this outcome was low due to risk of bias (incomplete outcome data) and sparse data (61 events). There was no difference between low dose mesalamine and placebo in the proportion of patients who had adverse events (RR 1.33, 95% CI 0.91 to 1.96; 3 studies, 342 patients) or withdrew due to adverse events (RR 1.21, 95% CI 0.75 to 1.95; 3 studies, 342 patients). High dose controlled-release mesalamine (4 g/day) was not superior to placebo, inducing a clinically non significant reduction in CDAI (MD -19.8 points, 95% CI -46.2 to 6.7; 3 studies, 615 patients), and was also inferior to budesonide (RR 0.56, 95% CI 0.40 to 0.78; 1 study, 182 patients, GRADE = low). While high dose delayed-release mesalamine (3 to 4.5 g/day) was not superior to placebo for induction of remission (RR 2.02, 95% CI 0.75 to 5.45; 1 study, 38 patients, GRADE = very low), no significant difference in efficacy was found when compared to conventional corticosteroids (RR 1.04, 95% CI 0.79 to 1.36; 3 studies, 178 patients, GRADE = moderate) or budesonide (RR 0.89, 95% CI 0.76 to 1.05; 1 study, 307 patients, GRADE = moderate). However, these trials were limited by risk of bias (incomplete outcome data) and sparse data (small numbers of events). There was a lack of good quality clinical trials comparing sulfasalazine with other mesalamine formulations. Adverse events that were commonly reported included headache, nausea, vomiting, abdominal pain and diarrhea. AUTHORS' CONCLUSIONS: Sulfasalazine is only modestly effective with a trend towards benefit over placebo and is inferior to corticosteroids for the treatment of mildly to moderately active Crohn's disease. Olsalazine and low dose mesalamine (1 to 2 g/day) are not superior to placebo. High dose mesalamine (3.2 to 4 g/day) is not more effective than placebo for inducing response or remission. However, trials assessing the efficacy of high dose mesalamine (4 to 4.5 g/day) compared to budesonide yielded conflicting results and firm conclusions cannot be made. Future large randomized controlled trials are needed to provide definitive evidence on the efficacy of aminosalicylates in active Crohn's disease.
[Mh] Termos MeSH primário: Anti-Inflamatórios não Esteroides/uso terapêutico
Doença de Crohn/tratamento farmacológico
Fármacos Gastrointestinais/uso terapêutico
Quimioterapia de Indução/métodos
[Mh] Termos MeSH secundário: Ácidos Aminossalicílicos/uso terapêutico
Budesonida/uso terapêutico
Preparações de Ação Retardada
Seres Humanos
Mesalamina/uso terapêutico
Ensaios Clínicos Controlados Aleatórios como Assunto
Sulfassalazina/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; RESEARCH SUPPORT, NON-U.S. GOV'T; REVIEW
[Nm] Nome de substância:
0 (Aminosalicylic Acids); 0 (Anti-Inflammatory Agents, Non-Steroidal); 0 (Delayed-Action Preparations); 0 (Gastrointestinal Agents); 3XC8GUZ6CB (Sulfasalazine); 4Q81I59GXC (Mesalamine); 51333-22-3 (Budesonide); ULS5I8J03O (olsalazine)
[Em] Mês de entrada:1609
[Cu] Atualização por classe:160802
[Lr] Data última revisão:
160802
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160704
[St] Status:MEDLINE
[do] DOI:10.1002/14651858.CD008870.pub2


  7 / 3006 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27367297
[Au] Autor:Grossi V; Hyams JS
[Ad] Endereço:a Division of Digestive Diseases, Hepatology, and Nutrition , Connecticut Children's Medical Center , Hartford , CT , USA.
[Ti] Título:The safety of treatment options for pediatric Crohn's disease.
[So] Source:Expert Opin Drug Saf;15(10):1383-90, 2016 Oct.
[Is] ISSN:1744-764X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: A severe clinical phenotype along with concern for ensuring normal growth and development has a major impact on treatment choices for children newly diagnosed with Crohn's disease (CD). AREAS COVERED: We review the increasingly outdated concept of 'conventional' therapy of pediatric CD based on aminosalicylates, corticosteroids, and immunomodulators for patients at high risk of complicated disease. Key safety concerns with each treatment are reviewed. EXPERT OPINION: There are minimal data supporting the use of aminosalicylates in the treatment of pediatric CD. Corticosteroids are effective short-term for improving signs and symptoms of disease but are ineffective for maintenance therapy. Thiopurines decrease corticosteroid dependence but may not alter progression to complicated disease requiring surgery. Concerns for lymphoma as well as hemophagocytic lymphohistiocytosis with thiopurines are valid. Further data are required on the efficacy and safety of methotrexate as an alternative immunomodulator. Though generally well tolerated and efficacious in most patients, anti-TNF-α therapy can be associated with both mild as well as more serious complications. Current data do not support an increased risk for malignancy associated with anti-TNF therapy alone in children. Anti-adhesion therapy appears to have a favorable safety profile but the experience in children is extremely limited.
[Mh] Termos MeSH primário: Doença de Crohn/tratamento farmacológico
Glucocorticoides/uso terapêutico
Fatores Imunológicos/uso terapêutico
[Mh] Termos MeSH secundário: Ácidos Aminossalicílicos/efeitos adversos
Ácidos Aminossalicílicos/uso terapêutico
Criança
Doença de Crohn/fisiopatologia
Progressão da Doença
Glucocorticoides/efeitos adversos
Seres Humanos
Fatores Imunológicos/efeitos adversos
Metotrexato/efeitos adversos
Metotrexato/uso terapêutico
Fator de Necrose Tumoral alfa/antagonistas & inibidores
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Aminosalicylic Acids); 0 (Glucocorticoids); 0 (Immunologic Factors); 0 (Tumor Necrosis Factor-alpha); YL5FZ2Y5U1 (Methotrexate)
[Em] Mês de entrada:1702
[Cu] Atualização por classe:170227
[Lr] Data última revisão:
170227
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160702
[St] Status:MEDLINE
[do] DOI:10.1080/14740338.2016.1203418


  8 / 3006 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27363268
[Au] Autor:Ji S; Wen Y; Lai Q; Li M; Zhang P
[Ad] Endereço:Department of Respiratory Diseases, Foshan First People's Hospital, Foshan 528000, China.
[Ti] Título:[Hypoxia combined with TNF-α induces apoptosis of cultured human pulmonary microvascular endothelial cells via activation of the STAT3 rather than ERK1/2 signaling pathway].
[So] Source:Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi;32(7):896-900, 2016 Jul.
[Is] ISSN:1007-8738
[Cp] País de publicação:China
[La] Idioma:chi
[Ab] Resumo:Objective To explore the effect of combined hypoxia and tumor necrosis factor α (TNF-α) on the apoptosis of human pulmonary microvascular endothelial cells (HPMVECs) and the involved signaling pathway mechanism. Methods Some HPMVECs were treated with hypoxia within 6, 12, or 24 hours, and the other cells were treated with TNF-α at the concentrations of 10, 20, 50, or 100 ng/mL. Cell activity was determined by MTT assay in each group to determine the best combined stimulatory conditions. Under the optimal costimulatory condition, the activity of caspase-3 was detected by flow cytometry, annexin V-FITC/PI double staining combined with flow cytometry was used to detect the apoptosis, Western blotting was performed to test the level of phosphorylated signal transducer and activator of transcription 3 (pSTAT3) and phosphorylated extracellular signal-regulated kinase 1/2 (pERK1/2). Results The cell activity was the lowest in 24-hour hypoxia group and 100 ng/mL TNF-α group. Therefore, we confirmed the combination of hypoxia for 24 hours and 100 ng/mL TNF-α as the costimulatory conditions. The caspase-3 activity and apoptosis rate in the combined treatment group were higher, compared with the other groups. The expression of pSTAT3, rather than pERK1/2, increased in the combined treatment group, compared with the control group. Moreover, the STAT3 inhibitor S3I-201 reduced the apoptosis rate in the combined treatment group. Conclusion Combined hypoxia and TNF-α could promote HPMVEC apoptosis by activating STAT3 rather than ERK1/2.
[Mh] Termos MeSH primário: Apoptose/efeitos dos fármacos
Células Endoteliais/efeitos dos fármacos
Proteína Quinase 1 Ativada por Mitógeno/metabolismo
Proteína Quinase 3 Ativada por Mitógeno/metabolismo
Fator de Transcrição STAT3/metabolismo
Fator de Necrose Tumoral alfa/farmacologia
[Mh] Termos MeSH secundário: Ácidos Aminossalicílicos/farmacologia
Benzenossulfonatos/farmacologia
Western Blotting
Caspase 3/metabolismo
Hipóxia Celular
Células Cultivadas
Células Endoteliais/metabolismo
Citometria de Fluxo
Seres Humanos
Pulmão/irrigação sanguínea
Sistema de Sinalização das MAP Quinases/efeitos dos fármacos
Microvasos/citologia
Fosforilação/efeitos dos fármacos
Fator de Transcrição STAT3/antagonistas & inibidores
Transdução de Sinais/efeitos dos fármacos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Aminosalicylic Acids); 0 (Benzenesulfonates); 0 (NSC 74859); 0 (STAT3 Transcription Factor); 0 (Tumor Necrosis Factor-alpha); EC 2.7.11.24 (MAPK1 protein, human); EC 2.7.11.24 (Mitogen-Activated Protein Kinase 1); EC 2.7.11.24 (Mitogen-Activated Protein Kinase 3); EC 3.4.22.- (Caspase 3)
[Em] Mês de entrada:1701
[Cu] Atualização por classe:170104
[Lr] Data última revisão:
170104
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160702
[St] Status:MEDLINE


  9 / 3006 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27289577
[Au] Autor:Zhang LL; Yang H; Xiao HP; Lu JM; Sha W; Zhang Q
[Ad] Endereço:Shanghai Key Laboratory of Tuberculosis, Shanghai Pulmonary Hospital, Medical School, Tongji University, Shanghai 200433, China.
[Ti] Título:[Determination of in vitro synergy by a checkerboard method when 3 core antimicrobial agents of the retreatment new scheme combined against MDR-MTB and XDR-MTB].
[So] Source:Zhonghua Jie He He Hu Xi Za Zhi;39(6):464-8, 2016 Jun.
[Is] ISSN:1001-0939
[Cp] País de publicação:China
[La] Idioma:chi
[Ab] Resumo:OBJECTIVE: In order to detect the in vitro synergistic effect of 4 drugs-pasiniazid (PA), moxifloxacin, rifabutin and rifapentini on multidrug-resistant mycobacterium tuberculosis (MDR-MTB) and extensively drug-resistant mycobacterium tuberculosis(XDR-MTB), which were core drugs of"The program of retreatment research of tuberculosis". METHOD: The checkerboard method was used to detect the minimum inhibitory concentration (MIC) of antituberculosis drug combination schemes (moxifloxacin-PA, moxifloxacin-PA-rifabutin and moxifloxacin-PA-rifapentini) to 40 strains of clinical drug resistant MTB(20 strains of MDR-MTB and 20 XDR-MTB) and the standard strain H37Rv, by calculating the fractional inhibitory concentration index of joint action in vitro to judge the combined effect, with fractional inhibitory concentration index(FICI)≤0.5 and FICI≤0.75 as the basis of 2 drugs and 3 drugs showing synergy. RESULTS: The FICI of moxifloxacin-PA scheme for DR-MTB was 0.125 to 1.000, only 5 strains with a FICI ≤0.5, showing synergistic effect. The FICI of moxifloxacin-Pa-rifabutin scheme with 20 strains of MDR-MTB ranged from 0.310 to 1.260, 10 strains with a FICI≤0.75, showing synergistic effect. The FICI of moxifloxacin-PA-rifabutin scheme with 20 strains of XDR-MTB ranged from 0.215 to 1.250, 11 strains with a FICI≤0.75, showing synergistic effect. The FICI of moxifloxacin-PA-rifapentini scheme with 20 strains of MDR-MTB ranged from 0.150 to 0.780, 19 strains with a FICI≤0.75, showing synergistic effect. The FICI of moxifloxacin-PA-rifapentini scheme with 20 strains of XDR-MTB ranged from 0.200 to 1.280, 16 strains with a FICI≤0.75, showing synergistic effect. CONCLUSIONS: The synergistic effect of moxifloxacin-PA scheme was poor, but showing better synergy when further combined with rifabutin or rifapentini. Rifabutin showed better effect than rifapentini, but the synergistic effect of moxifloxacin-PA-rifabutin combination scheme was poor than that of moxifloxacin-PA-rifapentini combination scheme.
[Mh] Termos MeSH primário: Antibióticos Antituberculose/uso terapêutico
Tuberculose Extensivamente Resistente a Medicamentos/tratamento farmacológico
Mycobacterium tuberculosis/efeitos dos fármacos
Tuberculose Resistente a Múltiplos Medicamentos/tratamento farmacológico
[Mh] Termos MeSH secundário: Ácidos Aminossalicílicos/uso terapêutico
Sinergismo Farmacológico
Quimioterapia Combinada
Fluoroquinolonas/uso terapêutico
Isoniazida/análogos & derivados
Isoniazida/uso terapêutico
Testes de Sensibilidade Microbiana
Retratamento
Rifabutina/uso terapêutico
Rifampina/análogos & derivados
Rifampina/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Aminosalicylic Acids); 0 (Antibiotics, Antitubercular); 0 (Fluoroquinolones); 1W306TDA6S (Rifabutin); 83J17CN0MN (pasiniazide); U188XYD42P (moxifloxacin); V83O1VOZ8L (Isoniazid); VJT6J7R4TR (Rifampin); XJM390A33U (rifapentine)
[Em] Mês de entrada:1701
[Cu] Atualização por classe:170123
[Lr] Data última revisão:
170123
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160613
[St] Status:MEDLINE
[do] DOI:10.3760/cma.j.issn.1001-0939.2016.06.013


  10 / 3006 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27261899
[Au] Autor:McConnell RA; Mahadevan U
[Ad] Endereço:Division of Gastroenterology, University of California, San Francisco, 1701 Divisadero Street, #120, San Francisco, CA 94115, USA.
[Ti] Título:Pregnancy and the Patient with Inflammatory Bowel Disease: Fertility, Treatment, Delivery, and Complications.
[So] Source:Gastroenterol Clin North Am;45(2):285-301, 2016 06.
[Is] ISSN:1558-1942
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:For many women with inflammatory bowel disease (IBD), the illness coincides with their childbearing years. IBD increases the risk of pregnancy complications and adverse pregnancy outcomes. The multidisciplinary care team should emphasize the importance of medication adherence to achieve preconception disease control and maintain corticosteroid-free remission throughout pregnancy. Medication adjustments to reduce fetal exposure may be considered on an individualized basis in quiescent disease; however, any benefits of such adjustments remain theoretic and there is risk of worsening disease activity. Mode of delivery is determined by obstetric indications, except for women with active perianal disease who should consider cesarean delivery.
[Mh] Termos MeSH primário: Ácidos Aminossalicílicos/uso terapêutico
Antibacterianos/uso terapêutico
Parto Obstétrico/métodos
Glucocorticoides/uso terapêutico
Imunossupressores/uso terapêutico
Infertilidade Feminina/terapia
Doenças Inflamatórias Intestinais/tratamento farmacológico
Complicações na Gravidez/tratamento farmacológico
[Mh] Termos MeSH secundário: Adalimumab/uso terapêutico
Anticorpos Monoclonais/uso terapêutico
Produtos Biológicos
Aleitamento Materno
Budesonida/uso terapêutico
Certolizumab Pegol/uso terapêutico
Feminino
Fármacos Gastrointestinais/uso terapêutico
Seres Humanos
Infertilidade Feminina/diagnóstico
Infertilidade Feminina/epidemiologia
Infertilidade Masculina/epidemiologia
Doenças Inflamatórias Intestinais/epidemiologia
Infliximab/uso terapêutico
Masculino
Natalizumab/uso terapêutico
Prednisona/uso terapêutico
Gravidez
Resultado da Gravidez
Taxa de Gravidez
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Aminosalicylic Acids); 0 (Anti-Bacterial Agents); 0 (Antibodies, Monoclonal); 0 (Biological Products); 0 (Gastrointestinal Agents); 0 (Glucocorticoids); 0 (Immunosuppressive Agents); 0 (Natalizumab); 51333-22-3 (Budesonide); 91X1KLU43E (golimumab); B72HH48FLU (Infliximab); FYS6T7F842 (Adalimumab); UMD07X179E (Certolizumab Pegol); VB0R961HZT (Prednisone)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170609
[Lr] Data última revisão:
170609
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160605
[St] Status:MEDLINE



página 1 de 301 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde